Table 1

Baseline characteristics of patients included in the analysis of predictors of outcomes and those excluded due to incomplete data. Values are median (IQR) or n (%), unless otherwise stated

	All n=60	Subgroup for Analysis of predictors of outcome
	All n=60	Included n=41	Excluded n=19	p Value
Age, mean (SD)	46 (14)	45 (15)	48 (11)	0.4
Female	39 (65%)	27 (66%)	12 (63%)	0.8
Symptom duration, months	9 (4–17)	9 (4–18)	8 (4–17)	0.8
ACPA positive	4 (7%)	3 (7%)	1 (5%)	1.0
Early Morning Stiffness ≥60 min	31 (52%)	19 (46%)	12 (63%)	0.3
RAI SJC44	3 (2–6)^a 2 (1–4)^a	3 (2–6) 2 (1–5)	2 (1–3)^a 2 (1–3)^a	0.1 0.7
CRP, mg/L	7 (0–23)	6 (0–22)	10 (0–27)	0.4
Patient VASDA, mm	43 (25–66)^a+b	45 (25–68)^b	34 (17–63)^a	0.7
DAS-CRP	2.3 (1.6–2.9)^b+c	2.3 (1.8–2.9)^b	1.8 (1.3–2.5)^c	0.2
HAQ	0.3 (0.1–0.9)^a+d	0.3 (0.1–0.9)^d	0.6 (0.1–1.1)^a	0.9
US of 26 joints at baseline: total GS score	9 (5–16)^e	9 (5–17)	NA^e	NA
Total PD score	1 (0–2)^e	1 (0–2)	NA^e	NA
Number of joints with GS≥ grade 2 Number of joints with PD≥ grade 1	2 (1–5)^e 1 (0–1)^e	2 (1–5) 1 (0–1)	NA^e	NA
Fulfilment of 2010 ACR/EULAR RA criteria with joint involvement determined clinically or by GS≥ grade 2 and/or PD≥ grade 1	4/42 (10%)	4 (10%)	NA^e	NA
Radiographic erosion in the hands and/or feet	4/55 (7%)	3 (7%)	1 (7%)^f	1.0

Missing data in ^a12, ^b8, ^c13, ^d6, ^e18 and ^f5 cases.
ACPA, anti-cyclic citrullinated protein antibody; ACR, American College of Rheumatology; CRP, C reactive protein; DAS-CRP, disease activity score; EULAR, European League Against Rheumatism; GS, grey scale; HAQ, Health Assessment Questionnaire; NA, not applicable (summary statistics not performed due to insufficient data); PD, power Doppler activity; RA, rheumatoid arthritis;RAI, Ritchie articular index; SJC44, swollen joint count of 44 joints; US, ultrasound; VASDA, visual analogue scale disease activity assessment.